131 related articles for article (PubMed ID: 34261976)
1. ERG Immunoreactivity in Blastic Hematolymphoid Neoplasms: Diagnostic Pitfall in the Workup of Undifferentiated Malignant Neoplasms.
Koo M; Natkunam Y
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):42-48. PubMed ID: 34261976
[TBL] [Abstract][Full Text] [Related]
2. Myeloid sarcoma and extramedullary hematopoiesis expand the spectrum of ERG-positive proliferations: an ancillary tool in the diagnosis.
Vargas AC; Turner J; Burchett I; Ho LL; Zumbo R; Gill AJ; Maclean FM
Hum Pathol; 2022 Jun; 124():1-13. PubMed ID: 35307404
[TBL] [Abstract][Full Text] [Related]
3. ERG and SALL4 expressions in SMARCB1/INI1-deficient tumors: a useful tool for distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Yamada Y; Hotokebuchi Y; Yamamoto H; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2015 Feb; 46(2):225-30. PubMed ID: 25479928
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Vascular Markers (Immunohistochemical Stains) in Soft Tissue Sarcomas.
Naeem N; Mushtaq S; Akhter N; Hussain M; Hassan U
J Coll Physicians Surg Pak; 2018 May; 28(5):352-356. PubMed ID: 29690962
[TBL] [Abstract][Full Text] [Related]
5. The transformation of isolated gastric myeloid sarcoma into acute myeloid leukemia presenting with a complex karyotype and TLS-ERG gene fusion: A case report.
Gao L; Xu Y; Tian Z; Xia J; Yuan Z; Chen D; Ren M
Medicine (Baltimore); 2022 May; 101(21):e29475. PubMed ID: 35623083
[TBL] [Abstract][Full Text] [Related]
6. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.
Miettinen M; Wang ZF; Paetau A; Tan SH; Dobi A; Srivastava S; Sesterhenn I
Am J Surg Pathol; 2011 Mar; 35(3):432-41. PubMed ID: 21317715
[TBL] [Abstract][Full Text] [Related]
7. State of the art in myeloid sarcoma.
Klco JM; Welch JS; Nguyen TT; Hurley MY; Kreisel FH; Hassan A; Lind AC; Frater JL
Int J Lab Hematol; 2011 Dec; 33(6):555-65. PubMed ID: 21883967
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and Pathologic Features of Myeloid Sarcoma].
Jiang YJ; Wang HX; Zhuang WC; Chen H; Zhang C; Li XM; Zhu GH; He Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):926-931. PubMed ID: 28641661
[TBL] [Abstract][Full Text] [Related]
9. Decrease of TET2 expression and increase of 5-hmC levels in myeloid sarcomas.
Xiao D; Shi Y; Fu C; Jia J; Pan Y; Jiang Y; Chen L; Liu S; Zhou W; Zhou J; Tao Y
Leuk Res; 2016 Mar; 42():75-9. PubMed ID: 26811000
[TBL] [Abstract][Full Text] [Related]
10. ERG expression in epithelioid sarcoma: a diagnostic pitfall.
Miettinen M; Wang Z; Sarlomo-Rikala M; Abdullaev Z; Pack SD; Fetsch JF
Am J Surg Pathol; 2013 Oct; 37(10):1580-5. PubMed ID: 23774169
[TBL] [Abstract][Full Text] [Related]
11. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.
Kang LC; Dunphy CH
Arch Pathol Lab Med; 2006 Feb; 130(2):153-7. PubMed ID: 16454553
[TBL] [Abstract][Full Text] [Related]
12. Histiocytic and Dendritic Cell Neoplasms.
Jones D
Surg Pathol Clin; 2010 Dec; 3(4):1165-83. PubMed ID: 26839303
[TBL] [Abstract][Full Text] [Related]
13. 013 (CD99) positivity in hematologic proliferations correlates with TdT positivity.
Robertson PB; Neiman RS; Worapongpaiboon S; John K; Orazi A
Mod Pathol; 1997 Apr; 10(4):277-82. PubMed ID: 9110287
[TBL] [Abstract][Full Text] [Related]
14. ERG Is a Useful Immunohistochemical Marker to Distinguish Leukemia Cutis From Nonneoplastic Leukocytic Infiltrates in the Skin.
Xu B; Naughton D; Busam K; Pulitzer M
Am J Dermatopathol; 2016 Sep; 38(9):672-7. PubMed ID: 26909589
[TBL] [Abstract][Full Text] [Related]
15. PAX-5: a valuable immunohistochemical marker in the differential diagnosis of lymphoid neoplasms.
Desouki MM; Post GR; Cherry D; Lazarchick J
Clin Med Res; 2010 Jul; 8(2):84-8. PubMed ID: 20660931
[TBL] [Abstract][Full Text] [Related]
16. Hematolymphoid lesions of the sinonasal tract.
Crane GM; Duffield AS
Semin Diagn Pathol; 2016 Mar; 33(2):71-80. PubMed ID: 26472692
[TBL] [Abstract][Full Text] [Related]
17. CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases.
Maeshima AM; Taniguchi H; Hattori D; Sasaki H; Hori Y; Makita S; Iwaki N; Fukuhara S; Munakata W; Suzuki T; Izutsu K
Hum Pathol; 2022 Jun; 124():14-23. PubMed ID: 35307403
[TBL] [Abstract][Full Text] [Related]
18. Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue.
Cannatella J; Ganapathi K; Horvai A
Arch Pathol Lab Med; 2020 Dec; 144(12):1547-1552. PubMed ID: 32167380
[TBL] [Abstract][Full Text] [Related]
19. Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses.
Zanelli M; Sanguedolce F; Zizzo M; Fragliasso V; Broggi G; Palicelli A; Loscocco GG; Cresta C; Caprera C; Corsi M; Martino G; Bisagni A; Marchetti M; Koufopoulos N; Parente P; Caltabiano R; Ascani S
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568745
[TBL] [Abstract][Full Text] [Related]
20. Hematolymphoid Malignancies Presenting with Spinal Epidural Mass and Spinal Cord Compression: A Case Series with Rare Entities.
Pandey S; Gokden M; Kazemi NJ; Post GR
Ann Clin Lab Sci; 2019 Nov; 49(6):818-828. PubMed ID: 31882434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
